Research programme: anti-CD19 chimeric antigen receptor T-cell therapy - NIPRO Corporation/ TC BioPharm

Drug Profile

Research programme: anti-CD19 chimeric antigen receptor T-cell therapy - NIPRO Corporation/ TC BioPharm

Latest Information Update: 12 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nipro Corporation; TC BioPharm
  • Class Antineoplastics; Antivirals; CAR-T cell therapies; Gene therapies
  • Mechanism of Action Immunostimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer; Viral infections

Most Recent Events

  • 07 Feb 2018 TC BioPharm and NIPRO Corporation agree to co-develop anti-CD19 chimeric antigen receptor T-cell therapy
  • 07 Feb 2018 Early research in Cancer in Japan (Parenteral)
  • 07 Feb 2018 Early research in Cancer in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top